Christian Baues

Radiation Oncologist / Lymphoma / ILROG / CyberKnife / UKKoeln / views are my own

[Graham Collins @graham74GC]

Fascinating talk by DeSelm - CAR-T worked less well on tumours not irradiated. Irradiation reduces phosphethalamine which increases DAG in CAR-T, promoting cell function.
#ICML2025

[Translational Radiobiology at UKER @translatradbio]

Liebe #radonc #radbio #radphys in Deutschland: Auf geht‘s zur @dfg_public Fachkollegienwahl!

[George Mikhaeel @GeorgeMikhaeel]

Very beautiful sunny day, perfect for #ILROG-London meeting. @ILROGTeam @ChelseaPinnix @BouthainaDabaja @umbertoricardi

[Christian Baues @ChristianBaues]

https://t.co/EblVv7Yzqk

4th ILROG Educational Conference in London. 9. - 10. Sept
Role of radiotherapy in combination with immunotherapy and CAR-T,
modern RT planning, developments in pathology, biology, PET, and new therapies.

We are looking forward! Join us!

[Rob Coppes @coppesrp]

Interesting review in
Ferroptosis, necroptosis, and pyroptosis in cancer: Crucial cell death... https://t.co/zwLnQYPSKr
@RadiotherapyOn1 #radiobiology @ESTRO_RT #radonc

[Daniel Molin @Dr_Daniel_Molin]

Carl DeSelm. CART and radiation. Low dose RT improves CART efficacy. Not only direct tumour killing. Timing important. Clinical data wanted.
ILROG Workshop.
#ICML17

[Daniel Molin @Dr_Daniel_Molin]

Stephen Ansell on micro environment in lymphoma. T-cell response, inhibitory mechanisms and ways to overcome them. Strategies: 1. CART, 2. immune checkpoint blockade, 3. bispecif abs, 4. engage innate immune syst, 5. RT.
ILROG workshop.
#ICML17

[Matthias Guckenberger @Mat_Guc]

(1/n)

PROSPECT – important study of high quality & relevance for rectal cancer pts
https://t.co/nEUvCAXiow

HOWEVER, misleading & dangerous interpretation of @nytimes „brutal effects of RT“
https://t.co/RCQJajzcii

[Matthias Guckenberger @Mat_Guc]

Single fraction 8Gy vs SBRT 20Gy for painful bone mets, n=126, mostly non-spine #ESTRO23
Complete pain response at 1 mo primary endpoint
👉 no difference at 1 mo
👉 improved in per protocol analysis after 3mo
👉 no increased toxicity
PATIENT SELECTION IS KEY

[Christian Baues @ChristianBaues]

George Mikhaeel gives an important and inspiring talk at #ESTRO2023 on the important role of radiotherapy in the complex treatment of malignant lymphoma. #Lymphoma #Radiotherapy #ILROG #ESTRO #vienna

[ISRSy @ISRSy]

Are you at #ESTRO23? Let us know by retweeting this post!

And don’t miss @ISRSy VP Dr. @SahgalArjun presenting tomorrow, after an excellent SBRT Bootcamp presentation today!

@ESTRO_RT #radonc #SBRT

[Lorenzo Galluzzi @deadoc80]

Happy to share our latest findings on #radiotherapy as a partner for CAR T cells, just out @cddpress. Kudos to Mayumi and Taka who did the heavy lifting, and to @DrMonicaGuzman who led us all here! @WeillCornell @ImmunoRadROBIN @WCM_MeyerCancer @WCMEnglanderIPM

[Elena Sperk @ElenaSperk]

Wie wertvoll spannende Formate zum #Austausch und für #Vernetzung sind, haben die KERNthemen in Dresden gezeigt! #Danke für den wertvollen Austausch zur #Zukunft der Strahlenforschung mit dem @BMBF_Bund und auch dem @BMUV und die tolle Organisation vom Projektträger Karlsruhe

[Nadeem Riaz @xrtGenomics]

Uh oh... 26% rate of elective failure from SBRT + Durva/Tremi + surgery in HPV+ HNSCC targetting only gross disease. Definitely needs some caution with this. https://t.co/RWI8qBQI8C. @imrtlee @sueyom @CJTsaiMDPhD @seanmmcbride h/t Narek

[Max Niyazi @MaxNiyazi]

New European ESTRO-EANO glioblastoma delineation guideline out-a thread 1/N

Awesome collab. between ESTRO& EANO, key facts of new standard:
➡️ margin reduction to 1.5 cm advised (all-comers)
➡️ take care of FLAIR dd tumor

@ESTRO_RT
@EANOassociation

https://t.co/ig07suZ1nb

[Matthias Guckenberger @Mat_Guc]

TACE vs. SBRT for HCC: randomized phase II TRENDY trial
- stoped early due to poor a accrual
- all endpoints significantly or numerically better after SBRT
👉 time to progression 19 vs 12 mo
👉 median OS 44 vs 37 mo
👉2a local control 100% vs 44%
CONGRATS
https://t.co/XQt9uNqiIs

[Daniel Molin @Dr_Daniel_Molin]

Yescarta CAR-T cells show improved overall survival compared to standard of care for early relapsed/refractory large B-cell lymphoma. Impressive.

[Radiotherapy & Oncology @RO_GreenJournal]

New article alert (Vol. 183)

Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy
Jiaqi Fan et al.

https://t.co/0vi9DiZEDy

https://t.co/UJtB2tDIeR

[Christian Baues @ChristianBaues]

Hot of the press!
Radiotherapy plus CAR T-cells with possible synergies.
Radiotherapy remains an exciting component in the immuno-therapy of malignant lymphomas. https://t.co/ioIXhQaqZb
@ILROGTeam @UKKoeln #DLBCL @ESTRO_RT #lymphoma #radiotherapy #Immunotherapy @ASTRO_org

[Cihan Gani @GI_RadOnc]

🚨OPERA Results are out
👉 148 rectal cancer patients rand to 45 Gy + 9 Gy or 45 Gy + 3 x 30 Gy (!!!) using Papillon
👉 Patients with early rectal tumors, Max cT3b
👉 An incredible organ preservation rate!
https://t.co/LSiMwLpRV9
Congratulations to JP Gerard and Sun Mynt. #radonc